Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 48


Tuberculosis infection control measures in health care facilities offering tb services in Ikeja local government area, Lagos, South West, Nigeria.

Kuyinu YA, Mohammed AS, Adeyeye OO, Odugbemi BA, Goodman OO, Odusanya OO.

BMC Infect Dis. 2016 Mar 15;16(1):126. doi: 10.1186/s12879-016-1453-y.


Youth friendly health services in a rural community of Lagos, Nigeria: are the youths receptive?

Wright KO, Oluwole E, Adeniran A, Kuyinu Y, Goodman O, Odusanya O.

Int J Adolesc Med Health. 2016 Jan 21. pii: /j/ijamh.ahead-of-print/ijamh-2015-0095/ijamh-2015-0095.xml. doi: 10.1515/ijamh-2015-0095. [Epub ahead of print]


Neonatal Jaundice: Knowledge, Attitude and practices of mothers in Mosan-Okunola community, Lagos, Nigeria.

Goodman OO, Kehinde OA, Odugbemi BA, Femi-Adebayo TT, Odusanya OO.

Niger Postgrad Med J. 2015 Jul-Sep;22(3):158-63. doi: 10.4103/1117-1936.170741.


Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators.

Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16.


CYP3A5 regulates prostate cancer cell growth by facilitating nuclear translocation of AR.

Mitra R, Goodman OB Jr.

Prostate. 2015 Apr 1;75(5):527-38. doi: 10.1002/pros.22940. Epub 2015 Jan 13.


Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.

Chao OS, Goodman OB Jr.

Mol Cancer Res. 2014 Dec;12(12):1755-66. doi: 10.1158/1541-7786.MCR-14-0173. Epub 2014 Aug 15.


Integrating circulating tumor cell data with imaging and serum prostate-specific antigen measurement for metastatic prostate cancer therapy management.

Goodman O, Schuur ER.

Case Rep Oncol. 2014 Mar 22;7(1):217-21. doi: 10.1159/000361042. eCollection 2014 Jan.


Enhanced detection of metastatic prostate cancer cells in human plasma with lipid bodies staining.

Mitra R, Goodman OB, Le TT.

BMC Cancer. 2014 Feb 15;14:91. doi: 10.1186/1471-2407-14-91.


Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.

Goodman OB Jr, Flaig TW, Molina A, Mulders PF, Fizazi K, Suttmann H, Li J, Kheoh T, de Bono JS, Scher HI.

Prostate Cancer Prostatic Dis. 2014 Mar;17(1):34-9. doi: 10.1038/pcan.2013.41. Epub 2013 Oct 1.


Abiraterone in metastatic prostate cancer without previous chemotherapy.

Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators.

N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10. Erratum in: N Engl J Med. 2013 Feb 7;368(6):584.


Detection of lipid-rich prostate circulating tumour cells with coherent anti-Stokes Raman scattering microscopy.

Mitra R, Chao O, Urasaki Y, Goodman OB, Le TT.

BMC Cancer. 2012 Nov 21;12:540. doi: 10.1186/1471-2407-12-540.


Urothelial bladder carcinoma with choriocarcinomatous differentiation presenting with a false-positive pregnancy test.

Rajabi B, Khoury J, Brewer C, Goodman OB Jr.

Am J Med Sci. 2013 Sep;346(3):256-8. doi: 10.1097/MAJ.0b013e318270d0f9.


Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.

Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS.

Lancet Oncol. 2012 Dec;13(12):1210-7. doi: 10.1016/S1470-2045(12)70473-4. Epub 2012 Nov 9.


Negative regulation of NEP expression by hypoxia.

Mitra R, Chao OS, Nanus DM, Goodman OB Jr.

Prostate. 2013 May;73(7):706-14. doi: 10.1002/pros.22613. Epub 2012 Nov 8.


Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS; COU-AA-301 Investigators.

Lancet Oncol. 2012 Oct;13(10):983-92. doi: 10.1016/S1470-2045(12)70379-0. Epub 2012 Sep 18. Erratum in: Lancet Oncol. 2012 Nov;13(11):e464. Lancet Oncol. 2014 Aug;15(9):e365.


Increased survival with enzalutamide in prostate cancer after chemotherapy.

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fl├ęchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators.

N Engl J Med. 2012 Sep 27;367(13):1187-97. Epub 2012 Aug 15.


The relevance of BRCA genetics to prostate cancer pathogenesis and treatment.

Sundararajan S, Ahmed A, Goodman OB Jr.

Clin Adv Hematol Oncol. 2011 Oct;9(10):748-55. Review.


A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.

Weber JS, Vogelzang NJ, Ernstoff MS, Goodman OB, Cranmer LD, Marshall JL, Miles S, Rosario D, Diamond DC, Qiu Z, Obrocea M, Bot A.

J Immunother. 2011 Sep;34(7):556-67. doi: 10.1097/CJI.0b013e3182280db1.


Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.

Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ, Ward DC.

Clin Genitourin Cancer. 2011 Sep;9(1):39-45. doi: 10.1016/j.clgc.2011.05.008. Epub 2011 Jul 1.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk